In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.

@article{Glekas2011InVI,
  title={In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.},
  author={Athanasios P Glekas and Nagavara Kishore Pillarsetty and Blesida J. Punzalan and Nahida Khan and Peter M. Smith-Jones and Steven M. Larson},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2011},
  volume={52 8},
  pages={1301-7}
}
UNLABELLED Imatinib mesylate is a tyrosine kinase inhibitor that was approved by the U.S. Food and Drug Administration in 2001 for treatment of many different stages of chronic myeloid leukemia and in 2002 for treatment of gastrointestinal stromal tumors. Imatinib is known to inhibit the dysregulated proliferation of chronic myeloid leukemia, which is associated with the Bcr-Abl kinase; in gastrointestinal stromal tumors, imatinib is known to act via c-Kit kinase inhibition. The objective of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Phenylamino-pyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

  • J Zimmermann, E Buchdunger, H Mett, T Meyer, NB Lydon, P. Traxler
  • Bioorg Med Chem Lett
  • 1996
Highly Influential
7 Excerpts

STI571 analogs: 18F-STI571 as potential agents for PET imaging of c-kit expression at a kinase level

  • Z Peng, W Bornman, A Pal
  • Presented at: 233rd ACS National Meeting;
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…